Nutritional and Metabolic Diseases

441 trials 157 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial Ended

2022-502076-23-00 osteopenia 4 2023-08-16
A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy p… Ended

2023-503949-65-00 Type 2 Diabetes 3 2023-08-07
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended

2022-500449-26-00 Type 2 diabetes mellitus (T2DM) 6 2023-08-03
A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dial… Ended

2023-503984-41-00 Hyyperkalemia in CKD stage IIIB to V patients 5 2023-08-02
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a rand… Ended

2023-510257-42-01 Type 2 diabetes 6 2023-07-25
An open-label, single-dose phase 1 study to evaluate the Absorption, Metabolism, and Excretion of [14C]-AZ-3102 in Healthy Male Subjects Ended

2023-504916-14-00 Glycosphingolipid lysosomal storage disorders 3 2023-07-13
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 4 2023-05-30
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/… Ended

2024-516455-40-00 Advanced liver fibrosis and/or mild liver cirrhosis 3 2023-05-25
GALOP : Oral glibenclamide in hyperglycaemia of the premature infant Ended

2024-512230-15-00 Transient hyperglycaemia in premature infants 4 2023-05-20
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhoti… Ended

2023-509704-14-00 Non-cirrhotic non-alcoholic steatohepatitis with fibros 4 2023-04-28
A study to compare how different substances (caffeine, warfarin, omeprazole, metoprolol, and midazolam) are handled by the body of healthy p… Ended

2024-514622-22-00 1. Patients with compensated liver cirrhosis due to any 3 2023-04-25
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute… Ended

2024-513706-56-00 Acute-on-chronic liver failure (ACLF) is characterized 4 2023-03-22
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Witho… Ended

2023-510470-13-00 Overweight and Obesity 4 2023-03-10
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Ended

2022-501426-38-00 Lipoprotein Disorder 4 2023-02-09
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 New onset type I diabetes 4 2023-01-27
Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease Ended

2022-501068-16-00 Insulin resistance 4 2022-12-14
A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi… Ended

2022-500594-13-00 "Non-Alcoholic Steatohepatatis (NASH) is the progressiv 4 2022-12-14
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Dose… Ended

2024-513119-29-00 PMM2-CDG 4 2022-12-02
Dual action weight loss in IIH - IIHDUAL Ended

2024-517120-19-02 Idiopathic Intracranial Hypertension 6 2022-09-02
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended

2024-510612-75-00 Participants with T2D and overweight 5 2022-08-31
Personalized dosing of immunosuppression after kidney transplantation by measuring the immune system functionality Ended

2022-500024-30-00 Post Kidney transplantation 4 2022-08-23